• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CPR Pharma Services launches Access2Asia service

CPR Pharma Services launches Access2Asia service

April 29, 2013
CenterWatch Staff

CPR Pharma Services, an Australian-based CRO, is launching Access2Asia, a service targeting U.S.-based companies wanting to access the Asia-Pacific region.

While access to therapeutically naive populations in Asia to conduct late phase studies is not new, CPR is focused on early phase studies, utilizing its network of experienced phase I units with access to various ethnicities to address this gap in the CRO market for small to medium biotech and pharma.

The Access2Asia service aims to connect U.S. companies with CPR and its network of clinical trial centers to deliver ethno-bridging studies; incorporation of ethnicity arms into phase I trials; and local management of phase IIa and IIb study support with providers that have the knowledge to navigate the local regulatory environment.

“CPR Pharma Services is the only CRO in the region that can offer a quick turnaround in early phase trials in Asia, as well as the opportunity for U.S. companies to have an on-the-ground expert managing all aspects of the trials,” said Jason Valentine, CEO of CPR.

Valentine also said the service allows U.S. companies to not only access “Western-style high quality clinical trials at a fraction of what it costs in the U.S. or Europe,” but also provides access to the growing Asian market. “Asia, and particularly China, has a growing middle class that wants access to pharmaceuticals. In order to access this market Western companies need to trial their drugs in the region. CPR can help these U.S. companies navigate the often complex regulatory systems across Asia.”

For example, Valentine said that gaining approval for a typical phase I trial in China can take up to 20 months. “By using Access2Asia a trial could be started in Australia in as little as 3-6 weeks and by incorporating an ethnicity arm into the study, the process of starting the regulatory process in China can start much sooner, potentially taking two years off of the current timeline for access to the Chinese market,” he said. “We can access Chinese populations in early stage development in Singapore and across Asia, which allows a biotech or pharma to jump start their regulatory process in China.”

For early stage clinical trials CPR can provide the bio-analytical services in its Singapore laboratory, as well as in its Adelaide facilities which are FDA-audited. For phase IIa and IIb trials CPR can manage and monitor the trials through its network of hospital sites across Asia as well as deal with local regulatory authorities through their local agents.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing